Infolettre
HTA Quarterly Spring 2026
In this edition, we discuss the risks of relying on immature data for survival projections in oncology and the importance of selecting robust models to guide HTA decisions. We also explore key challenges and developments in HTA within the UK and Germany, including the impact of limited clinical evidence on NICE appraisals, with strategies to improve submission outcomes, and recent updates to Germany’s AMNOG dossier requirements, highlighting the evolution to trend-based estimates to better align benefit assessments with statutory health insurance patient populations.
Heard on the street
“The HTACG estimates that it will initiate around 50 joint clinical assessments (JCAs) of medicines… and for the first time, JCAs of selected high-risk medical devices.”
— EU’s Member State Coordination Group on Health Technology Assessment (HTACG) outlining key strategic priorities for 2026
Source: Health Technology Assessment – 2026 Work Programme adopted
Source: Health Technology Assessment – 2026 Work Programme adopted
HTA by the numbers
200%
The new HTACG target of 50 JCAs in 2026 is twice the target number of JCAs for 2025.
Sources:
Health Technology Assessment – 2026 Work Programme adopted
New EU rules for health technology assessments become effective | European Medicines Agency (EMA)
Sources:
Health Technology Assessment – 2026 Work Programme adopted
New EU rules for health technology assessments become effective | European Medicines Agency (EMA)
Entrez en contact avec notre équipe
Notre équipe d’experts de la valeur se consacre à la transformation des données probantes, des informations sur les politiques et des renseignements sur le marché en stratégies efficaces d’accès au marché mondial. Laissez-nous vous aider à naviguer dans le paysage complexe des soins de santé d’aujourd’hui en toute confiance. Contactez-nous pour découvrir comment nous pouvons vous aider à atteindre vos objectifs.
